Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Takeda Pharmaceutical experienced a dramatic increase in trading volume, with about 8.85 million shares changing hands, marking a 292% rise from the previous day's volume.
• Morgan Stanley upgraded Takeda’s rating from "equal weight" to "overweight," indicating a more favorable outlook for the company's stock.
• In its latest earnings report, Takeda missed consensus estimates, reporting $0.16 EPS against a projected $0.24 and revenue of $7.34 billion compared to an expected $8.02 billion.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 8,851,016 shares changed hands during trading, an increase of 292% from the previous session's volume of 2,258,672 shares.The stock last traded at $13.55 and had previously closed at $14.32.

Takeda Pharmaceutical Price Performance

The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. The company has a 50-day moving average price of $14.87 and a 200-day moving average price of $14.50. The company has a market capitalization of $44.94 billion, a price-to-earnings ratio of 47.08 and a beta of 0.23.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.52%. The business had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. On average, equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Large investors have recently bought and sold shares of the company. American Century Companies Inc. raised its stake in shares of Takeda Pharmaceutical by 6.0% during the 4th quarter. American Century Companies Inc. now owns 301,087 shares of the company's stock worth $3,986,000 after purchasing an additional 17,103 shares in the last quarter. LPL Financial LLC grew its holdings in Takeda Pharmaceutical by 1.9% in the 4th quarter. LPL Financial LLC now owns 186,652 shares of the company's stock valued at $2,471,000 after buying an additional 3,564 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Takeda Pharmaceutical by 94.5% in the 4th quarter. JPMorgan Chase & Co. now owns 83,826 shares of the company's stock valued at $1,110,000 after buying an additional 40,721 shares in the last quarter. Blair William & Co. IL grew its holdings in Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after buying an additional 913 shares in the last quarter. Finally, Orion Portfolio Solutions LLC acquired a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth $172,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.